NASDAQ:FTXH First Trust Nasdaq Pharmaceuticals ETF (FTXH) Price, Holdings, & News $25.79 +0.09 (+0.33%) As of 11:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsOptions ChainOwnershipRatingsShort InterestTrendsBuy This Stock About First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get FTXH alerts:Sign Up Key Stats Today's Range$25.79▼$26.0050-Day Range$23.57▼$28.7252-Week Range$23.29▼$29.72Volume1,034 shsAverage Volume3,912 shsMarket Capitalization$14.19 millionAssets Under Management$14.16 millionDividend Yield1.86%Net Expense Ratio0.60%Aggregate RatingModerate Buy ETF OverviewThe First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.Read More… First Trust Nasdaq Pharmaceuticals ETF ExpensesTypeFTXHHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.60%0.57%0.56%0.53%0.53%Other Expenses0.00%0.30%0.48%0.43%0.52%Total Expense0.60%0.70%0.72%0.68%0.71%Fee Waiver0.00%-0.45%-0.49%-0.29%-0.54%Net Expense0.60%0.61%0.63%0.62%0.60% Receive FTXH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for First Trust Nasdaq Pharmaceuticals ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address FTXH ETF News HeadlinesFirst Trust Nasdaq BuyWrite Income ETF declares $0.207 dividendJanuary 22, 2025 | msn.com3 Health Care ETFs You'll Want to Own When the Market RecoversAugust 3, 2022 | stocknews.comThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang said, "The ChatGPT moment for robotics is right around the corner." In fact, I believe these robots could impact 65 million Americans lives — this year. And one stock — currently priced around $7 — could be the biggest winner.April 30, 2025 | Weiss Ratings (Ad)Surprising Analyst 12-Month Target For FTXHMay 25, 2022 | nasdaq.comFirst Trust Nasdaq Pharmaceuticals ETF declares quarterly distribution of $0.0488March 25, 2022 | seekingalpha.comSolid Q4 Earnings Fail to Impress Pharma ETFsFebruary 22, 2022 | nasdaq.comSee More Headlines FTXH ETF - Frequently Asked Questions How have FTXH shares performed this year? First Trust Nasdaq Pharmaceuticals ETF's stock was trading at $26.97 at the beginning of the year. Since then, FTXH stock has decreased by 4.4% and is now trading at $25.7950. View the best growth stocks for 2025 here. Who are First Trust Nasdaq Pharmaceuticals ETF's major shareholders? Top institutional investors of First Trust Nasdaq Pharmaceuticals ETF include Envestnet Asset Management Inc. (3.42%), Cambridge Investment Research Advisors Inc. (3.01%) and NBC Securities Inc. (0.20%). How do I buy shares of First Trust Nasdaq Pharmaceuticals ETF? Shares of FTXH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of First Trust Nasdaq Pharmaceuticals ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that First Trust Nasdaq Pharmaceuticals ETF investors own include Digirad (DRAD), RAIT Financial Trust (RAS), Cummins (CMI), Auxly Cannabis Group (CBWTF), Blueknight Energy Partners (BKEP), Biocept (BIOC) and BioCorRx (BICX). Fund Details IssuerFirst Trust Fund NameFirst Trust Nasdaq Pharmaceuticals ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:FTXH Inception Date9/20/2016 Fund ManagerDaniel Lindquist, Jon Erickson, David McGarel, Roger Testin, Stan Ueland, Chris Peterson, Erik Russo WebN/A Phone14089961010Fund Focus Asset ClassEquity BenchmarkNasdaq US Smart Pharmaceuticals Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings51 Fund Statistics Assets Under Management$14.01 million Average Daily Volume$3,622.00 Discount/Premium-0.04% Administrator, Advisor and Custodian AdministratorThe Bank of New York Mellon Corporation AdvisorFirst Trust Advisors L.P. CustodianThe Bank of New York Mellon Corporation DistributorFirst Trust Portfolios L.P. Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerOld Mission Options OptionableN/A Short Interest300 shs Miscellaneous Outstanding Shares550,000Beta0.70 Creation Unit50,000 Creation Fee$500.00 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report Top 10 FTXH HoldingsJohnson & Johnson (NYSE:JNJ)Holding Weight: 7.72%Merck & Co., Inc. (NYSE:MRK)Holding Weight: 7.11%AbbVie (NYSE:ABBV)Holding Weight: 7.09%Pfizer (NYSE:PFE)Holding Weight: 7.08%Bristol-Myers Squibb (NYSE:BMY)Holding Weight: 6.71%Eli Lilly and Company (NYSE:LLY)Holding Weight: 3.84%Gilead Sciences (NASDAQ:GILD)Holding Weight: 3.82%United Therapeutics (NASDAQ:UTHR)Holding Weight: 3.81%Zoetis (NYSE:ZTS)Holding Weight: 3.74%Amgen (NASDAQ:AMGN)Holding Weight: 3.73%Full Holdings DetailsFTXH Sector ExposureFTXH Industry Exposure This page (NASDAQ:FTXH) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding First Trust Nasdaq Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share First Trust Nasdaq Pharmaceuticals ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.